Compare AIRI & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIRI | SNGX |
|---|---|---|
| Founded | 1979 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5M | 13.8M |
| IPO Year | N/A | 1987 |
| Metric | AIRI | SNGX |
|---|---|---|
| Price | $2.88 | $1.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 27.5K | ★ 304.6K |
| Earning Date | 11-14-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $50,031,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.53 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.77 | $1.09 |
| 52 Week High | $4.70 | $6.23 |
| Indicator | AIRI | SNGX |
|---|---|---|
| Relative Strength Index (RSI) | 39.79 | 52.12 |
| Support Level | $2.95 | $1.55 |
| Resistance Level | $3.15 | $1.70 |
| Average True Range (ATR) | 0.11 | 0.11 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 14.26 | 62.69 |
Air Industries Group is an aerospace and defense company. Its manufactures and designs structural parts and assemblies that focus on flight safety, including landing gear, arresting gear, engine mounts, flight controls, throttle quadrants, jet engines, and other components. The company also provides sheet metal fabrication of aerostructures, tube bending, and welding services.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).